Essa Pharma Inc. to Adjourn Special Meeting to September 29, 2025

Core Viewpoint - ESSA Pharma Inc. has announced the adjournment of a special meeting to allow for further discussions regarding the financial terms of its transaction with XenoTherapeutics, Inc. [1][2] Group 1: Special Meeting Details - The special meeting, originally scheduled for September 10, 2025, will now take place on September 29, 2025, at 2:00 p.m. Pacific Time, and will be conducted online [3]. - Shareholders who have already voted do not need to take any further action at this time [3]. Group 2: Transaction Overview - The transaction involves XenoTherapeutics acquiring all issued and outstanding common shares of ESSA [1]. - Discussions are ongoing regarding the estimated cash forecast and the upfront cash available for distribution to shareholders in the transaction [2]. Group 3: Legal Proceedings - The approval hearing for the transaction, initially set for September 12, 2025, has been postponed, with a new date to be announced [4]. Group 4: Company Background - ESSA Pharma Inc. is a pharmaceutical company focused on developing novel therapies for prostate cancer [5].